PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration

Molecular Pharmaceutics

Volumn 12, Issue 3, 2015, Pages 794-809

  Chan, Linda J ^a   Bulitta, Jürgen B ^a   Ascher, David B ^b   Haynes, John Michael ^a   McLeod, Victoria M ^a   Porter, Christopher J H ^a   Williams, Charlotte C ^c   Kaminskas, Lisa M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CSIRO   (Australia)

Author keywords

HER2; lymphatic; monoclonal antibody; PEGylation; pharmacokinetics; population modeling; S ADAPT; trastuzumab

Indexed keywords

TRASTUZUMAB; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN M; MACROGOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANNULATION; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SYNTHESIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HYDROPHILICITY; IN VITRO STUDY; MALE; MOLECULAR SIZE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; THORACIC DUCT; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; BLOOD; CAPILLARY PERMEABILITY; CHEMISTRY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH; LYMPHATIC SYSTEM; METABOLIC CLEARANCE RATE; METABOLISM; PHARMACEUTICS; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOPHARMACEUTICS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOGLOBULIN M; INJECTIONS, SUBCUTANEOUS; LYMPH; LYMPHATIC SYSTEM; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; TRASTUZUMAB;

EID: 84929086831     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp5006189     Document Type: Article

References (66)

1. Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future Br. J. Pharmacol. 2009, 157, 220-33
2. Nelson, A. L.; Dhimolea, E.; Reichert, J. M. Development trends for human monoclonal antibody therapeutics Nat. Rev. Drug Discovery 2010, 9, 767-74
3. Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.; Mackey, J.; Glaspy, J.; Chan, A.; Pawlicki, M.; Pinter, T.; Valero, V.; Liu, M. C.; Sauter, G.; von Minckwitz, G.; Visco, F.; Bee, V.; Buyse, M.; Bendahmane, B.; Tabah-Fisch, I.; Lindsay, M. A.; Riva, A.; Crown, J. Breast Cancer International Research, G. Adjuvant trastuzumab in HER2-positive breast cancer N. Engl. J. Med. 2011, 365, 1273-83
4. McKeage, K.; Perry, C. M. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2 Drugs 2002, 62, 209-43
5. Orman, J. S.; Perry, C. M. Trastuzumab: in HER2 and hormone receptor co-positive metastatic breast cancer Drugs 2007, 67, 2781-9
6. Hazard, H.; Hansen, N. Sentinel Lymphadenectomy in Breast Cancer. In Advances in Breast Cancer Management, 2nd ed.; Gradishar, W.; Wood, W., Eds.; Springer: New York, 2008; Vol. 141, pp 11-36.
7. Hack, T. F.; Cohen, L.; Katz, J.; Robson, L. S.; Goss, P. Physical and psychological morbidity after axillary lymph node dissection for breast cancer J. Clin. Oncol. 1999, 17, 143-9
8. Giuliano, A. E.; Jones, R. C.; Brennan, M.; Statman, R. Sentinel lymphadenectomy in breast cancer J. Clin. Oncol. 1997, 15, 2345-50
9. Chen, J.; Wang, L.; Yao, Q.; Ling, R.; Li, K.; Wang, H. Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer Breast Cancer Res. 2004, 6, R474-7
10. Dahlberg, A. M.; Kaminskas, L. M.; Smith, A.; Nicolazzo, J. A.; Porter, C. J. H.; Bulitta, J. B.; McIntosh, M. P. The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats Mol. Pharmaceutics 2014, 11, 496-504
11. McLennan, D. N.; Porter, C. J. H.; Charman, S. A. Subcutaneous drug delivery and the role of the lymphatics Drug Discovery Today: Technol. 2005, 2, 89-96
12. Kaminskas, L. M.; Kota, J.; McLeod, V. M.; Kelly, B. D.; Karellas, P.; Porter, C. J. H. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following sc administration in rats J. Controlled Release 2009, 140, 108-16
13. Kaminskas, L. M.; Ascher, D. B.; McLeod, V. M.; Herold, M. J.; Le, C. P.; Sloan, E. K.; Porter, C. J. H. PEGylation of interferon alpha2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases J. Controlled Release 2013, 168, 200-8
14. Leveque, D. Subcutaneous administration of anticancer agents Anticancer Res. 2014, 34, 1579-86
15. Shpilberg, O.; Jackisch, C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase Br. J. Cancer 2013, 109, 1556-61
16. Vugmeyster, Y.; Xu, X.; Theil, F. P.; Khawli, L. A.; Leach, M. W. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges World J. Biol. Chem. 2012, 3, 73-92
17. Kagan, L. Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins Drug Metab. Dispos. 2014, 42 (11) 1890-905
18. Supersaxo, A.; Hein, W. R.; Steffen, H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration Pharm. Res. 1990, 7, 167-9
19. Porter, C. J. H.; Charman, S. A. Lymphatic transport of proteins after subcutaneous administration J. Pharm. Sci. 2000, 89, 297-310
20. Swartz, M. A.; Skobe, M. Lymphatic function, lymphangiogenesis, and cancer metastasis Microsc. Res. Tech. 2001, 55, 92-9
21. Porter, C. J. H.; Edwards, G. A.; Charman, S. A. Lymphatic transport of proteins after s.c. injection: implications of animal model selection Adv. Drug Delivery Rev. 2001, 50, 157-71
22. Swartz, M. A. The physiology of the lymphatic system Adv. Drug Delivery Rev. 2001, 50, 3-20
23. McLennan, D. N.; Porter, C. J. H.; Edwards, G. A.; Brumm, M.; Martin, S. W.; Charman, S. A. Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep Pharm. Res. 2003, 20, 1156-62
24. McLennan, D. N.; Porter, C. J. H.; Edwards, G. A.; Martin, S. W.; Heatherington, A. C.; Charman, S. A. Lymphatic absorption is the primary contributor to the systemic availability of Epoetin alfa following subcutaneous administration to sheep J. Pharmacol. Exp. Ther. 2005, 313, 345-51
25. Charman, S. A.; McLennan, D. N.; Edwards, G. A.; Porter, C. J. H. Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model Pharm. Res. 2001, 18, 1620-6
26. Charman, S. A.; Segrave, A. M.; Edwards, G. A.; Porter, C. J. H. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection J. Pharm. Sci. 2000, 89, 168-77
27. Bumbaca, D.; Boswell, C. A.; Fielder, P. J.; Khawli, L. A. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics AAPS J. 2012, 14, 554-8
28. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U. S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives Angew. Chem., Int. Ed. 2010, 49, 6288-308
29. Baumann, A.; Tuerck, D.; Prabhu, S.; Dickmann, L.; Sims, J. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? Drug Discovery Today 2014, 19 (10) 1623-31
30. Deckert, P. M.; Jungbluth, A.; Montalto, N.; Clark, M. A.; Finn, R. D.; Williams, C., Jr.; Richards, E. C.; Panageas, K. S.; Old, L. J.; Welt, S. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts Int. J. Cancer 2000, 87, 382-90
31. Kitamura, K.; Takahashi, T.; Yamaguchi, T.; Noguchi, A.; Noguchi, A.; Takashina, K.; Tsurumi, H.; Inagake, M.; Toyokuni, T.; Hakomori, S. Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy Cancer Res. 1991, 51, 4310-5
32. Banerjee, S. S.; Aher, N.; Patil, R.; Khandare, J. Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications J. Drug Delivery 2012, 2012, 103973
33. Veronese, F. M. Peptide and protein PEGylation: a review of problems and solutions Biomaterials 2001, 22, 405-17
34. Hayashi, Y.; Matsui, H.; Takagi, T. Membrane protein molecular weight determined by low-angle laser light-scattering photometry coupled with high-performance gel chromatography Methods Enzymol. 1989, 172, 514-28
35. Ascher, D. B.; Wielens, J.; Nero, T. L.; Doughty, L.; Morton, C. J.; Parker, M. W. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA Sci. Rep. 2014, 4, 4765
36. Kaminskas, L. M.; Kelly, B. D.; McLeod, V. M.; Sberna, G.; Boyd, B. J.; Owen, D. J.; Porter, C. J. H. Capping methotrexate alpha-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers Mol. Pharmaceutics 2011, 8, 338-49
37. Boyd, B. J.; Kaminskas, L. M.; Karellas, P.; Krippner, G.; Lessene, R.; Porter, C. J. H. Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats Mol. Pharmaceutics 2006, 3, 614-27
38. Girardet, R. E.; Benninghoff, D. L. Long term physiologic study of thoracic duct lymph and lymphocytes in rat and man Lymphology 1977, 10, 36-44
39. Kaminskas, L. M.; McLeod, V. M.; Ascher, D. B.; Ryan, G. M.; Jones, S.; Haynes, J. M.; Trevaskis, N. L.; Chan, L. J.; Sloan, E. K.; Finnin, B. A.; Williamson, M.; Velkov, T.; Williams, E. D.; Kelly, B. D.; Owen, D. J.; Porter, C. J. H. Methotrexate-Conjugated PEGylated Dendrimers Show Differential Patterns of Deposition and Activity in Tumor-Burdened Lymph Nodes after Intravenous and Subcutaneous Administration in Rats Mol. Pharmaceutics 2015, 12 (2) 432-43
40. Ryan, G. M.; Kaminskas, L. M.; Bulitta, J. B.; McIntosh, M. P.; Owen, D. J.; Porter, C. J. H. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin J. Controlled Release 2013, 172, 128-36
41. Bulitta, J. B.; Bingolbali, A.; Shin, B. S.; Landersdorfer, C. B. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT AAPS J. 2011, 13, 201-11
42. Bulitta, J. B.; Duffull, S. B.; Kinzig-Schippers, M.; Holzgrabe, U.; Stephan, U.; Drusano, G. L.; Sorgel, F. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers Antimicrob. Agents Chemother. 2007, 51, 2497-507
43. Brendel, K.; Comets, E.; Laffont, C.; Laveille, C.; Mentre, F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide Pharm. Res. 2006, 23, 2036-49
44. Bulitta, J. B.; Landersdorfer, C. B. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models AAPS J. 2011, 13, 9258-9259
45. Kaminskas, L. M.; McLeod, V. M.; Porter, C. J. H.; Boyd, B. J. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance J. Pharm. Sci. 2011, 100, 5069-77
46. Owen, S. C.; Patel, N.; Logie, J.; Pan, G.; Persson, H.; Moffat, J.; Sidhu, S. S.; Shoichet, M. S. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles J. Controlled Release 2013, 172, 395-404
47. Hatakeyama, H.; Akita, H.; Harashima, H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Delivery Rev. 2011, 63, 152-60
48. Rath, T.; Kuo, T. T.; Baker, K.; Qiao, S. W.; Kobayashi, K.; Yoshida, M.; Roopenian, D.; Fiebiger, E.; Lencer, W. I.; Blumberg, R. S. The immunologic functions of the neonatal Fc receptor for IgG J. Clin. Immunol. 2013, 33 (Suppl. 1) S9-17
49. Tzaban, S.; Massol, R. H.; Yen, E.; Hamman, W.; Frank, S. R.; Lapierre, L. A.; Hansen, S. H.; Goldenring, J. R.; Blumberg, R. S.; Lencer, W. I. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity J. Cell Biol. 2009, 185, 673-84
50. Roseng, L.; Tolleshaug, H.; Berg, T. Uptake, intracellular transport, and degradation of polyethylene glycol-modified asialofetuin in hepatocytes J. Biol. Chem. 1992, 267, 22987-93
51. Roopenian, D. C.; Akilesh, S. FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 2007, 7, 715-25
52. Valabrega, G.; Montemurro, F.; Aglietta, M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer Ann. Oncol. 2007, 18, 977-984
53. Gajria, D.; Chandarlapaty, S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies Expert Rev. Anticancer Ther. 2011, 11, 263-75
54. Nahta, R. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer ISRN Oncol. 2012, 2012, 428062
55. Hudis, C. A. Trastuzumab-mechanism of action and use in clinical practice N. Engl. J. Med. 2007, 357, 39-51
56. Longva, K. E.; Pedersen, N. M.; Haslekas, C.; Stang, E.; Madshus, I. H. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2 Int. J. Cancer 2005, 116, 359-67
57. Li, L.; Gardner, I.; Rose, R.; Jamei, M. Incorporating Target Shedding Into a Minimal PBPK-TMDD Model for Monoclonal Antibodies CPT: Pharmacometrics Syst. Pharmacol. 2014, 3, e96
58. Kaminskas, L. M.; Porter, C. J. H. Targeting the lymphatics using dendritic polymers (dendrimers) Adv. Drug Delivery Rev. 2011, 63, 890-900
59. Zhan, X.; Tran, K. K.; Shen, H. Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration Mol. Pharmaceutics 2012, 9, 3442-51
60. Saifer, M. G.; Williams, L. D.; Sobczyk, M. A.; Michaels, S. J.; Sherman, M. R. Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins Mol. Immunol. 2014, 57, 236-46
61. Sherman, M. R.; Williams, L. D.; Sobczyk, M. A.; Michaels, S. J.; Saifer, M. G. Role of the methoxy group in immune responses to mPEG-protein conjugates Bioconjugate Chem. 2012, 23, 485-99
62. Armstrong, J. K.; Hempel, G.; Koling, S.; Chan, L. S.; Fisher, T.; Meiselman, H. J.; Garratty, G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients Cancer 2007, 110, 103-11
63. McLennan, D. N.; Porter, C. J. H.; Edwards, G. A.; Martin, S. W.; Charman, S. A. Molecular weight is a primary determinant for lymphatic absorption of proteins following subcutaneous administration to sheep AAPS PharmSci 2002, 4, W4041
64. McLennan, D. N.; Porter, C. J. H.; Edwards, G. A.; Heatherington, A. C.; Martin, S. W.; Charman, S. A. The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep Pharm. Res. 2006, 23, 2060-6
65. Kota, J.; Machavaram, K. K.; McLennan, D. N.; Edwards, G. A.; Porter, C. J. H.; Charman, S. A. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model Drug Metab. Dispos. 2007, 35, 2211-7
66. Oussoren, C.; Storm, G. Liposomes to target the lymphatics by subcutaneous administration Adv. Drug Delivery Rev. 2001, 50, 143-56